SAFETY AND TOLERABILITY OF EXTENDED (96 WEEKS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IN GENOTYPE D PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B

被引：0
|
作者：
Lampertico, Pietro [1 ]
Vigano, Mauro [1 ]
Di Costanzo, Giovan Giuseppe [2 ]
Sagnelli, Evangelista [3 ]
Fasano, Massimo [4 ]
Di Marco, Vito [5 ]
Boninsegna, Sara [6 ]
Farci, Patrizia [7 ]
Fargion, Silvia [8 ]
Giuberti, Tiziana [9 ]
Iannacone, Claudio [10 ]
Massetto, Benedetta [11 ]
Martins, Eduardo B. [12 ]
Colombo, Massimo [1 ]
机构：
[1] Univ Milan, Div Gastroenterol 1, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[2] Cardarelli Hosp, Liver Unit, Naples, Italy
[3] SS Anna & Sebastiano Hosp, Infect Dis Unit, Caserta, Italy
[4] Univ Bari, Clin Infect Dis, Bari, Italy
[5] Univ Palermo, Gastroenterol & Hepatol Unit, Di Bi MIS, Palermo, Italy
[6] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy
[7] Univ Cagliari, Dept Med Sci, Monserrato, Italy
[8] Univ Milan, Dept Internal Med, IRCCS Fdn Policlin, Milan, Italy
[9] Azienda Osped Univ Parma, Unit Infect Dis & Hepatol, Parma, Italy
[10] SPARC Consulting, Milan, Italy
[11] Roche, Monza, Italy
[12] Genentech Inc, San Francisco, CA 94080 USA
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
135
引用
收藏
页码：387A / 387A
页数：1
相关论文
共 50 条
  • [21] Peginterferon alfa-2a (40KD) (PEGASYS®) in combination with ribavirin in African American and Caucasian patients with chronic hepatitis CHCV genotype 1:: Safety and tolerability.
    Howell, C
    Jeffers, LS
    Cassidy, W
    Reddy, R
    Sheridan, S
    Ho, I
    Khouri, S
    Harb, G
    HEPATOLOGY, 2003, 38 (04) : 319A - 319A
  • [22] A GENOTYPE-SPECIFIC BASELINE SCORE TO PREDICT RESPONSE AT 48 WEEKS POST-TREATMENT TO PEGINTERFERON ALFA-2A IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B
    Lampertico, P.
    Messinger, D.
    Cornberg, M.
    Brunetto, M.
    Petersen, J.
    Kennedy, P.
    Asselah, T.
    Rothe, V.
    Caputo, A.
    Bakalos, G.
    Pavlovic, V.
    Papatheodoridis, G. V.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S599 - S600
  • [23] COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A (40KD) IN HBEAG-POSITIVE CHRONIC HEPATITIS B IN POLAND
    Jakubczyk, M.
    Paweska, J.
    Niewada, M.
    Berak, H.
    Szkultecka-Debek, M.
    Russel-Szymczyk, M.
    VALUE IN HEALTH, 2011, 14 (07) : A275 - A275
  • [24] Role of baseline and on-treatment quantitative HBeAg in predicting response to peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy in chronic hepatitis B
    Fried, Michael W.
    Lau, George K. K.
    Liaw, Yun-Fan
    Luo, Kang-Xian
    Piratvisuth, Teerha
    Cooksley, Graham
    Marcellin, Patrick
    Thongsawat, Satawat
    Button, Peter
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A72 - A72
  • [25] Predictive factors in treatment of chronic hepatitis c (cHC) patients with peginterferon alfa-2a (40KD) and ribavirin
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Berrid
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A839 - A839
  • [26] Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) and ribavirin in patients with or without drug use
    Zehnter, Elmar
    Mauss, Stefan
    John, Christine
    Heyne, Renate
    Moeller, Bernd
    Lutz, Thomas
    Bokemeyer, Bernd
    Kihn, Robert
    Moog, Gero
    Vornkahl, Heike
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A840
  • [27] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    HEPATOLOGY, 2003, 38 (04) : 244A - 245A
  • [28] Virological and biochemical response in patients with HBeAG-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) with or without lamivudine: Results of 4-year follow-up
    Marcellin, P.
    Piratvisuth, T.
    Brunetto, M.
    Bonino, F.
    Lau, G. K. K.
    Farci, P.
    Yurdaydin, C.
    Wu, J.
    Popescu, M.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S46 - S46
  • [29] Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    Marcellin, P
    Lau, GKK
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Lu, ZM
    Piratvisuth, T
    Germanidis, G
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Button, P
    Pluck, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (12): : 1206 - 1217
  • [30] Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study
    Wirth, Stefan
    Zhang, Hongfei
    Hardikar, Winita
    Schwarz, Kathleen B.
    Sokal, Etienne
    Yang, Weibo
    Fan, Huimin
    Morozov, Vyacheslav
    Mao, Qing
    Deng, Hong
    Huang, Yang
    Yang, Lei
    Frey, Nicolas
    Nasmyth-Miller, Clare
    Pavlovic, Vedran
    Wat, Cynthia
    HEPATOLOGY, 2018, 68 (05) : 1681 - 1694
12345